Delving into the Latest Updates on Racanisodamine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Racanisodamine Hydrochloride, Raceanisidamine Hydrochloride, Raceanisodamide

+ [5]

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesEye DiseasesOther Diseases

Active Indication

MyopiaShock, Septic

Inactive Indication-

Originator Organization

Tianjin Jinyao Pharmaceutical Co., Ltd.

Active Organization

Yichang Humanwell Pharmaceuticals Co., Ltd.

Tianjin Jinyao Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 1981),

MyopiaShock, Septic

Regulation-

Login to view timeline

Structure

Molecular FormulaC17H23NO4

InChIKeyWTQYWNWRJNXDEG-UHFFFAOYSA-N

CAS Registry17659-49-3

Objective: To observe the efficacy and feasibility of a new therapy using a combination of different anticholinergic eyedrops in controlling myopia progression and axial prolongation in adolescents. Methods: Between July 2013 and June 2014, a total of 150 myopia adolescents aged 6-12 years were recruited at the clinic of Tongji Hospital in Shanghai. Participants were assigned in a 1∶2∶2 ratio to placebo group (no medication), combined treatment group (0.5% racanisodamine eyedrops were used twice a day during semesters, 1% atropine eyedrops were used before sleep during vacation) and atropine group (1% atropine eyedrops were used before sleep everyday). All subjects wore glasses. Visual acuity, best corrected visual acuity, cycloplegic refraction, corneal curvature, axial length, intraocular pressure, fundus and adverse events were recorded every 6 months during follow-up for 24 months. Results: At baseline, there was no significant difference in age,equivalent spherical mirror number and axial length among the three groups (all P>0.05). At the end of the second year,the mean myopia progression (changes of spherical equivalent) was -2.34 (-2.93,-1.75) D,-0.63 (-1.00,-0.50) D and -0.25 (-0.50,-0.06) D in placebo group, combined treatment group and atropine group, respectively (P<0.001), and there was statistically significant difference between each two groups (all P<0.001). The axial length change of each group were (1.51±0.23) mm, (0.69±0.30) mm and (0.31±0.30) mm, respectively (P<0.001), and there was statistically significant difference between each two groups (all P<0.001). Conclusion: Therapy using a combination of different anticholinergic eyedrops can effectively control the progression of myopia and axial prolongation in adolescents, and increase the compliance of children and the safety of drug use.

01 Sep 2014·Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology

[Regulative effects of vessel active drugs on extremital skin temperature of experimental animals exposed to cold].

Article

Author: Yang, Dan-feng ; Zhang, Li ; Wang, Jun ; Wang, Hai ; Liu, Jia-Ying ; Zhang, Ying ; An, Yu-lin ; Li, Xi ; Xiao, Zhong-hai

OBJECTIVEUsing an experimental model of animals exposed to cold to evaluate the regulative effects of prazosin hydrochloride (Pra) and racanisodamine (Ani) on extremital skin temperature of rats and mice.METHODSEighty animals were randomly divided into eight groups according to the drug dosage. After been administered with drugs by intragastric at room temperature for 60 min, the animals were moved into specified temperature (5 degrees C,18 degrees C) environment and the skin temperatures at the 1/3 site at the proximal end of tail were measured by infrared camera on 180 min and 300 min. Effects of drug were evaluated by changes in tail skin temperatures.RESULTSPra and Ani combination raised the extremital skin temperature of experimental animals significantly in a dose-dependent manner, while single use of Pra was not potent to rats and less potent to mice, and single use of Ani could not raise extremital skin temperature of both rats and mice. Change of rectal temperature in mice showed that Pra and Ani combination did not affect core temperature.CONCLUSIONPra and Ani combination could significantly raise extremital skin temperature of rats and mice exposed to cold, and would not affect their core (rectal) temperature.

01 May 2012·Spectrochimica Acta Part A: Molecular and Biomolecular SpectroscopyQ2 · CHEMISTRY

Mn-doped ZnS quantum dots for the room-temperature phosphorescence detection of raceanisodamine hydrochloride and atropine sulfate in biological fluids

Q2 · CHEMISTRY

Article

Author: Hui Wu ; Zhefeng Fan

Now, the development of quantum dots (QDs)-based fluorescence sensors become very quickly, but as phosphorescence compared to fluorescent has many advantages, like longer shine time and emission wavelength. Therefore, the phosphorescence properties of QDs and their potential for phosphorescence detection have raised great concerns. In this paper, a novel room-temperature phosphorescence (RTP) quenching method was developed by Mn-doped ZnS quantum dots (QDs). The developed method is employed for detection of the raceanisodamine hydrochloride and atropine sulfate in biological fluids. The results showed a high selectivity of the Mn-doped ZnS QDs toward these medicines by phosphorescence quenching. Under the optimized experimental conditions, the detection limits (3s) for raceanisodamine hydrochloride and atropine sulfate were 0.11 μM, 0.09 μM, respectively. The relative standard deviations for eleven replicate detections of 2.0 μM were 0.92-1.6%. The recovery of spiked solutions in human urine and serum samples ranged from 95% to 104%.

100 Deals associated with Racanisodamine

Login to view more data